At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,726 enrolled
Drug / intervention
Fluarix® +1 morebiological
Likely dose
Boostrix® 0.3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate Immunogenicity and Safety of Boostrix When Co-administered With Fluarix in Subjects 19 Years of Age and Older
In Brief
A Phase 3 clinical trial evaluating Fluarix® and Boostrix® for Acellular Pertussis and 2 related conditions. Completed, enrolled 1,726 participants across 12 sites.
Detailed Summary
The current study will provide information for the use of Boostrix concomitantly with influenza vaccine in adults aged 19-64 years. This study will also provide safety and immunogenicity data in a cohort of adults aged greater than or equal to 65 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcellular Pertussis, Diphtheria, Tetanus
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2006
Enrollment StartOct 2006
Primary CompletionFeb 2007
TodayJul 2026
First PostedOct 9, 2006
Enrollment StartOct 23, 2006
Primary CompletionFeb 28, 2007
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 19.7 years ago
Interventions
Fluarix®biological
GSK Biologicals' inactivated influenza split virus vaccine.
Boostrix®biological
GSK Biologicals' tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.